Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| RHYTHM PHARMACEUTICALS | 11 | 3 | -3,00 % | ||
| AMGEN | 9 | 27 | -0,63 % | ||
| BIOCRYST PHARMACEUTICALS | 9 | - | -2,91 % | ||
| IMMUNITYBIO | 7 | 3 | +10,72 % | ||
| BIONTECH | 5 | 13 | -1,28 % | ||
| MODERNA | 4 | 16 | +1,11 % | ||
| GILEAD SCIENCES | 4 | 5 | -1,87 % | ||
| CYTOKINETICS | 4 | 1 | 0,00 % | ||
| APPLIED THERAPEUTICS | 4 | - | -44,33 % | ||
| AVADEL PHARMACEUTICALS | 3 | 6 | -0,55 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:42 | Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug | 1 | Benzinga.com | ||
| 18:46 | Arcus cancels work on Gilead-partnered cancer combo after trial setback | 4 | BioPharma Dive | ||
| 18:34 | Jefferies hebt Kursziel für Immunitybio nach positivem EMA-Votum auf 9 US-Dollar an | 3 | Investing.com Deutsch | ||
| 18:30 | Jefferies raises Immunitybio stock price target to $9 on European regulatory progress | 3 | Investing.com | ||
| 18:06 | ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy | 1 | Benzinga.com | ||
| 17:58 | ImmunityBio-Aktie legt nach positiver EMA-Empfehlung für Blasenkrebstherapie zu | 3 | Investing.com Deutsch | ||
| 17:54 | Berichte über Knappheit : Sanofi und Seqirus liefern weiter Grippeimpfstoffe aus | 6 | Pharmazeutische Zeitung | ||
| 17:46 | BioCryst Pharma: TD Cowen bestätigt Kaufempfehlung nach pädiatrischer Zulassung für Orladeyo | 2 | Investing.com Deutsch | ||
| 17:42 | FDA Approves Amgen's Drug For Rare Muscle Disorder | 2 | Benzinga.com | ||
| 17:34 | JAMA zeichnet Studie zu Bluthochdruck-Medikament von Mineralys als Spitzenforschung 2025 aus | 1 | Investing.com Deutsch | ||
| 17:30 | BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval | 1 | Investing.com | ||
| 17:30 | Mineralys hypertension drug trial featured in JAMA's top research of 2025 | 1 | Investing.com | ||
| 17:26 | Sanofi - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17:06 | EMA recommends rejecting Anavex's blarcamesine for Alzheimer's | 7 | Seeking Alpha | ||
| 17:06 | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | 41 | GlobeNewswire (Europe) | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| 16:54 | ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week | 19 | Seeking Alpha | ||
| 16:50 | Eilmeldung am Abend: BIONTECH SE ADR zeigt neue Spannung | 37 | Maximilian Berger | ||
| 16:46 | Praxis tees up another approval filing; Geron turns to layoffs | 3 | BioPharma Dive | ||
| 16:35 | INCYTE CORP - 8-K, Current Report | - | SEC Filings | ||
| 16:30 | BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug | 2 | Benzinga.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .